An Open, Multicenter Phase II Study to Evaluate the Safety and Efficacy of KL-A167 Injection in Relapsed or Refractory Classical Hodgkin's Lymphoma

Classical Hodgkin Lymphoma Clinical Trial

Official title:

An Open, Multicenter Phase II Study to Evaluate the Safety and Efficacy of KL-A167 Injection in Relapsed or Refractory Classical Hodgkin's Lymphoma

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03580564
• Other study ID #: KL167-?-03-CTP
• Status: Completed
• Phase: Phase 2
• Start date: August 1, 2018
• Est. completion date: January 13, 2022

Study information

• Verified date: October 2023
• Source: Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The study is to evaluate the efficacy of KL-A167 a in subjects with relapsed or refractory classical Hodgkin lymphoma (cHL), as measured by Overall Response Rate (ORR) per the Lugano Classification

Recruitment information / eligibility

• Status: Completed
• Enrollment: 109
• Est. completion date: January 13, 2022
• Est. primary completion date: August 22, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• 18 years and older

• Histopathological confirmed classical Hodgkin's lymphoma

• Relapsed/refractory cHL include:subject with no response to or with progression after ASCT ;subject which failed failed second line and above chemtherapy;subject which didn't achieve PR after 2 cycles or didn't achieve CR after 4 cycles

• At least one measurable disease (long axis>15 mm and short axis>5 mm,or both axis>10 mm)

• ECOG performance status of 0 or 12

• Subject must have adequate organ functions and meet requirements on laboratory values.:Count of Blood Cells: absolute neutrophil count (ANC) = 1.0 × 109 / L; platelet count (PLT) = 50 × 109 / L; hemoglobin content (HGB) = 7.0 g / Dl; Liver function: serum total bilirubin (TBIL) = 1.5 × normal upper limit (ULN); alanine aminotransferase (ALT) and aspartate aminotransferase (AST) = 3 × ULN,with the exception of patients with hepatic metastases (ALT and AST = 5 × ULN) and patients with hepatic metastases or Gilbert's syndrome (total bilirubin = 3 × ULN)Renal function: serum creatinine (Cr) = 1.5 × ULN or Creatinine clearance rate(CCR)=50 mL/min;International normalized ratio (INR) = 1.5 x ULN ;Thyroid function: thyroid stimulating hormone (TSH) in normal range.

• Prior chemotherapy, radiotherapy, immunotherapy or investigational therapy (including Chinese herbal medicine and Chinese patent medicine) used to control cancer including locoregional treatment must have been completed = 4 weeks before the first dose of KL-A167(Mitomycin or nitroso must have been completed = 6 weeks), and all treatment-related adverse events (except alopecia) are stable and have either returned to baseline or Grade 0/1

• Subjects of reproductive potential must be willing to use adequate contraception during the course of the study and through 6 months after the last dose of study medication

• Subject has voluntarily agreed to participate by giving written informed consent.

Exclusion Criteria:

• Nodular lymphocyte-predominant Hodgkin lymphoma or gray zone lymphoma.

• Known central nervous system lymphoma.

• Prior malignancy except for curatively treated carcinoma in situ of the cervix or breast ,Superficial bladder cancer,and Squamous cell carcinoma in situ

• History of severe hypersensitivity reaction to monoclonal antibodies

• Prior exposure to any anti-PD-1, anti-PD-L1 or anti-CTLA-4 antibody.

• need the other anticancer therapy during the study

• Received any anticancer vaccine or other medications for immunomodulatory receptor preparations

• Received HSCT

• Received ASCT in the past 3 months

• Serious acute or chronic infection requiring systemic therapy.

• Subject with active autoimmune disease or history of autoimmune disease with high risk of recurrence.

• Conditions requiring systemic treatment with either corticosteroids (> 10 mg daily Prednisone equivalent) or other immunosuppressive medications within 14 days of first dose of KL-A167

• serious medical diseases, ex Suffering from heart failure (New York Heart Association standard III or IV), ischemic heart disease (such as myocardial infarction or angina), congestive heart failure and other cardiovascular diseases, uncontrolled diabetes(fasting blood glucose=10 mmol/L), uncontrolled high blood pressure(Systolic> 150 mmHg and / or diastolic> 100 mmHg), LVEF<50%

• QTcF>450 msec

• Known active HBV or HCV infection.

• Known HIV infection.

• Has history of interstitial lung disease or non-infectious pneumonitis. Subjects with prior drug-induced or radiation-induced pneumonitis who are asymptomatic are eligible.

• Known active pulmonary tuberculosis

• Has history of AE related with immune system during the Immunotherapy

• Received a live vaccine within 4 weeks of the first dose of study medication or plan to receive live vaccine during study period.

• Known neurological or psychiatric diseases

• Ongoing alcohol or drug abuse

• Pregnancy (absence to be confirmed by serum ß-human chorionic gonadotropin test) or breastfeeding

• Participation in another clinical trial within the past 4 weeks

• Other significant disease that in the investigator's opinion should exclude the subject from the trial

Related Conditions & MeSH terms

• Classical Hodgkin Lymphoma
• Hodgkin Disease
• Lymphoma

Intervention

Drug:
• KL-A167
KL-A167 900 mg intravenously (IV) every-2-weeks (Q2W)

Locations

Country	Name	City	State
China	Cancer Hospital Chinese Academy of Medical Sciences	Beijing	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Overall Response Rate	Overall Response Rate (ORR) defined as the proportion of subjects who achieves a best response of CR or PR, assessed by IRC per the Lugano Classification	Up to 2years
Secondary	Progression-free Survival (PFS)	From the first dose of KL-A167 to the date of PD or death, whichever occurs first	Up to 2years
Secondary	Duration of Response (DOR)	From the date that response criteria are first met to the date that PD is objectively documented or death, whichever occurs first	Up to 2years
Secondary	Overall Survival (OS)	From the first dose of KL-A167 to the date of death	Up to 2years
Secondary	Time to Response	From the date of the first dose of KL-A167 to the time the response criteria are first met	Up to 2years